ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Palbociclib (Palbociclib Viatris)

Palbociclib Viatris is indicated for the treatment of hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer. in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1).… Show the full indication

Palbociclib Viatris is indicated for the treatment of hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer. in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1). In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

Generic
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Viatris Limited

Research

Oncology · ESMO Open · 2026-06-11

In 120 patients with high-risk HR+/HER2− metastatic breast cancer, first-line palbociclib + ET improved median time-to-treatment failure vs mono-chemotherapy (17.2 vs 6.1 months; HR 0.46). OS did not differ; haematological toxicity was higher (96.8% vs 70.7%).

RCTn = 120
Schmidt et al. First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
Oncology · ESMO Open · 2026-03-10

Phase 2 RCT in 70 patients with previously treated HR-positive, HER2-negative metastatic breast cancer: palbociclib 100 mg vs 125 mg with endocrine therapy cut grade ≥3 neutropenia (33% vs 56%; P=0.04). Median PFS 6.28 vs 9.28 months, not significant.

RCTn = 70 patients
Jacob et al. TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
Oncology · Cancer Treat Rev · 2025-12-16

Systematic review of 23 studies in HR+/HER2- breast cancer: CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone raised grade 3/4 QTc prolongation risk (RR 1.83, driven by ribociclib) and VTE risk (RR 2.57, highest with abemaciclib).

Meta-analysisn = 23 studies
Hoo et al. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.